Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Alcestobart (DB28487)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05609370	A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer	Treatment	Alcestobart (DB28487) Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Tislelizumab (DB14922)